New funding of £1.26M granted to QV Bioelectronics for advancements in investigating innovative brain cancer therapy
In a significant development for the field of bioelectronic medicine, QV Bioelectronics is advancing its GRACE Electric Field Therapy device, a promising technology designed to treat brain tumors, including glioblastoma. The device, which is still in the advanced stages of development, delivers low-intensity electric fields that disrupt tumor cell division and growth, similar to tumor treating fields (TTF) therapy.
The GRACE system is unique in its optimized electric field parameters and delivery methods, designed to enhance tumor targeting while minimizing side effects. This could make it more user-friendly and effective than previous iterations of electric field therapies.
QV Bioelectronics has received a 1.26 million GBP grant under the Biomedical Catalyst program, which will support key preclinical, regulatory, and clinical readiness activities for GRACE. The company has emphasized innovative bioelectric mechanisms intended to improve treatment specificity and patient outcomes.
While traditional TTF devices have received regulatory approvals such as FDA clearance, QV Bioelectronics’ GRACE device is still in investigational status, undergoing studies to establish clinical benefits and meet regulatory requirements.
If clinical trials confirm its effectiveness, GRACE Electric Field Therapy could become a valuable adjunct to standard treatments like surgery, radiation, and chemotherapy, potentially improving progression-free survival and overall outcomes for glioblastoma patients. The non-invasive nature of the approach might also reduce systemic toxicity, enhancing patients’ quality of life.
The University of Edinburgh and NHS Lothian are contributing to the development of GRACE, with the University of Edinburgh expressing excitement about the prospect of the first in human study for the device. QV Bioelectronics is working to establish GRACE as a future first-line treatment for glioblastoma, with potential applications in paediatric and metastatic brain tumors as well.
Recent preclinical studies have demonstrated strong efficacy with QV Bioelectronics’ technology, and the company has reported 'encouraging' safety and efficacy data. They have secured over 6 million GBP in grant funding and equity investment, and the funding received will enable QV Bioelectronics to achieve key milestones as they move their world-first technology towards patients for the first time.
However, it's important to note that as of the current paragraph, GRACE is still in pre-clinical development and is not yet approved for use in humans. No clinical trial of GRACE is currently ongoing. For the most current info, checking the company’s announcements and clinical trial registries would be advisable.
In the broader context, current treatments for brain cancer have limited effectiveness and poor outcomes, with glioblastoma, the most aggressive and common primary brain tumor in adults, having one of the poorest prognoses in oncology. The success of the GRACE device, if it proves effective in clinical trials, could open doors to new modalities for managing not just glioblastoma but other resistant tumors.
This article does not contain advertisements and maintains factual accuracy, staying faithful to the given information. For more updates on QV Bioelectronics and the GRACE Electric Field Therapy device, please follow reputable news sources and the company's official announcements.
The GRACE Electric Field Therapy device, under development by QV Bioelectronics, shows promise in treating medical-conditions such as brain tumors, including glioblastoma, by using science to deliver low-intensity electric fields to disrupt tumor cell division and growth, similar to tumor treating fields (TTF) therapy. If clinical trials confirm its effectiveness, it could become a valuable adjunct to standard treatments like surgery, radiation, and chemotherapy, potentially improving health-and-wellness outcomes for glioblastoma patients.
